Justice Community Opioid Innovation Network (JCOIN)

National Survey of Substance Use Services in Jails

The availability, accessibility, and use of services for substance use disorders.

For questions about this survey, please email JCOINJailSurvey@norc.org or call (877) 396-4064.





About the Survey

The purpose of this survey is to learn more about the availability, accessibility, and use of substance use disorder services for persons involved in the criminal justice system. This survey is an activity of the Justice Community Opioid Innovation Network (JCOIN), a National Institute on Drug Abuse (NIDA) research initiative. NORC at the University of Chicago is a non-profit research organization that is conducting this survey on behalf of JCOIN.

The survey will take 10-15 minutes to complete. Your decision to participate in this survey is voluntary. You can choose to skip any questions you wish. NORC follows strict procedures to protect your information. We will only use your responses for statistical analysis and report them in aggregate.

Please email JCOINJailSurvey@norc.org or call 877-396-4064 with questions or concerns about this study. If you have any questions or concerns about your rights as a participant, please contact the NORC IRB Manager toll-free at (866) 309-0542 or by e-mail at irb@norc.org.

If you agree to participate in the survey, please follow the instructions below. By returning this completed survey, you:

- Indicate you have read the information provided above.
- Voluntarily agree to participate in this survey.
- Understand you have the right to withdraw as a participant at any time or refuse to answer any questions you do not want to answer.

Instructions

Identify a Staff Member

A staff member who can speak to substance use disorder screening and treatment protocols in your jail should complete this survey, and more than one person may need to contribute in order to complete this survey as accurately as possible.

Complete the Survey via Paper, Web, or Phone

Mail it back to NORC at the University of Chicago using the envelope provided or you may complete the survey online by visiting our secure link at **JCOINsurvey.norc.org** and entering your unique PIN provided in your invitation letter. If you prefer to complete the survey with an interviewer by phone, call NORC at 877-396-4064.

Select a Timeframe for Your Responses

The purpose of this interview is to capture the services provided during a 12-month time period. The 12-month reporting period will be selected by each jail. Our preference is that you use the most recent calendar or fiscal year. Several interview questions will refer to the "past year" or "past 12-months." Please indicate below the **latest** calendar or fiscal year for which your jail will be reporting on.

Year start:				Year end:	//	
N	1onth	Day	Year	Month	Day	Year

Include Information for Your Facility

When completing the survey, please include information for the facility named on your invitation email/letter. If the name provided applies to more than one facility, please select the biggest facility (based on rated capacity) to which the name applies. For this survey, information for the following should be included:

- Jails and other confinement facilities—including detention centers that are either privately owned and operated or administered by two or more governments (or a board composed of representatives from two or more governments).
- Temporary holding or lockup facilities if they are part of your combined function.
- Detainees held FOR other jurisdictions, including federal authorities, state prison authorities, American Indian or Alaska Native tribal governments, and other local jail jurisdictions (for example, holding inmates in your facility, on behalf of another county).

Do not include information for:

- Services for individuals held BY other jurisdictions (for example, another county housing inmates at their facility on your behalf).
- Services for individuals under community corrections or supervision who are NOT detained, including electronic monitoring, probation, parole, or diversion.

Clearly Mark Your Answers This survey contains several types of questions. Please s	select only one re	sponse option unle	ss otherwise	e noted.
1 For some questions, you answer the question by marking a	a box, like this:			
¹ ☑ Yes ² ☐ No				
You are sometimes told to skip over questions in this survey ou what question to answer next, like this:	ey. When this happo	ens, you will see an a	rrow with a no	te that tells
¹□ Yes → Skip to question 5 ²□ No				
Questi	onnaire			
a Please provide your contact information.	Who compri sentenced)?	ses the jail's population	on (pre-trial ar	nd
Name:	¹□ Males only	/ only		
Job title:	³☐ Both male			
Phone:	3 Which of the that apply.	following primarily o	perate this jai	l? Select all
Email: Please provide the full name and the contact information for the jail or facility for which you are completing the survey.	³ ☐ A regional or Unified ⁴ ☐ A court, sh	n, or other municipality public entity, Departm	ent of Correction	ons (DOC),
Facility name:		el best describes the concluding general health		
Phone number:	¹ ☐ Direct serv	vices (i.e., all healthcar	e services pro	vided by jail
Email:	contracted	d (i.e., all healthcare se I vendor(s)/provider(s)) a combination of direc	·	•
Complete the table below to indicate how many staff are empl was estimated or based on jail records.	oyed by the jail and	check the box indica	te whether tha	at number
			Was the numb	er provided
		Number of Persons	Estimated?	Based on jail records?
In the past 12 months, how many correctional officers were employed by the	jail?			
In the past 12 months, how many licensed healthcare providers were employed by the jail to provide general medical services (i.e., these staff were jail employees)?				
In the past 12 months, how many licensed addiction treatment providers were employed by the jail (i.e., these staff were jail employees)?				
In the past 12 months, how many licensed healthcare providers were contracted by the jail to provide general medical care (i.e., these staff were employees of a contracted vendor)?				
In the past 12 months, how many licensed addiction treatment providers were (i.e., staff were employees of a contracted vendor)?	e contracted by the jail			

	-		ou don't know the exact number.	
	Number of Persons		How has this number changed since 2019	
How many people were admitted to the jail?		☐ Estimated ☐ Based on jail records	☐ Increased ☐ Decreased ☐ No change	
What was the average daily population of the jail?		☐ Estimated ☐ Based on jail records	☐ Increased ☐ Decreased ☐ No change	
How many people were released from the jail?		☐ Estimated ☐ Based on jail records	☐ Increased ☐ Decreased ☐ No change	
What is the rated capacity of the jail? Rated capacity is the number of beds or inmates assigned by		☐ Estimated ☐ Based on jail records	☐ Increased ☐ Decreased ☐ No change	
a rating official to institutions within the jurisdiction.				
	Length of Stay days/months/years		How has the average length changed since 2019?	
For those released in the past 12 months, what was the average length of stay in the jail?		☐ Estimated ☐ Based on jail records	☐ Increased ☐ Decreased ☐ No change	
Comments or explanations for the survey team about le	nath of stay:			
since March 2020, how many individuals were re pecifically to minimize the risk of transmitting (vithin the jail?		intake to help identify sub opioid, stimulant, and oth	ssment methods are used during ostance use problems (i.e., alcohol, er drug)? Check all that apply. Skip is hol or other substance use disorders.	
Was this number: ☐ Estimated ☐ Based on jail records How does the jail determine which individuals we creened for possible alcohol use disorder? Sempply. ☐ Universal screening (everyone is screened)		used to screen for possi	I questionnaire (e.g., CAGE, COWS) ble substance use disorder a physician, nurse, or other clinician	
 □ Screening based on presenting charges (e.g., I order □ Jail follows a protocol set by Department of Colother entity 	,		alcohol and other substance use es not screen for alcohol or other	
other entity Use of the control of		¹ □ Physician (MD or DO) ² □ Nurse (including nurse practitioner, advanced practice		
Other (specify):			practitioner, advanced practice ed practical nurse, physician	
☐ Jail does not screen for alcohol problems		³ □ Psychologist, social wor		
ow does the jail determine which individuals w creened for possible opioid or other substance isorders? Select all that apply.		5 ☐ Other (specify):	Stail	
 ☐ Universal screening (everyone is screened) ☐ Screening based on presenting charges (e.g., I order ☐ Jail follows a protocol set by Department of Coother entity 	ŕ	disorder using an instrum	w many people admitted to the alcohol or other substance use ent, formal assessment or exam? or alcohol or other substance use	
☐ Screening based on individual request/need☐ Other (specify):		¹ All persons admitted ² A high majority (75%-99 ³ At least half (50%-74%)	Was the number provided 1 ☐ Estimated?	

9b	Of the people who were screened in many screened positive for possible Skip if jail does not screen for alcohol u	alcohol use disorder?	9	Since 2019, has the change in the propused the following	ortion (or	percentage	e) of individ	uals who	
	¹ ☐ A high majority (at least 75%)	Was the number		Substance	Increase	Decrease	No change	Don't know	
	² At least half (50%-74%)	provided ¹☐ Estimated?		Alcohol					
	³ ☐ Less than half (30%-49%) ⁴ ☐ Few (15%-30%)	² Based on screening		Prescription opioids					
	⁵ Very few (less than 15%)	records?		Heroin					
	$^{6}\square$ Not able to estimate a range.			Fentanyl					
9c	many screened positive for possible	opioid use disorder		Cocaine or crack cocaine					
(OUD)? (This includes heroin, fentanyl, and pres pain medications). Skip if jail does not screen for st disorders.		• • •		Methamphetamines					
		not screen for substance use		Prescription stimulants					
	¹ ☐ A high majority (at least 75%)	Was the number		Hallucinogens					
	² At least half (50%-74%)	provided ¹ ☐ Estimated?	12	a Is any kind of subst				support	
	³ ☐ Less than half (30%-49%) ⁴ ☐ Few (15%-30%)	² Based on screening	1	available to people	while they	are in this	jail?		
	⁵ Very few (less than 15%)	records?		¹□ Yes					
	6 Not able to estimate a range.			2 \square No → Skip to q	uestion 19				
Of the people who were screened in the past 12 months, how many people screened positive for a possible stimulant use disorder? (This includes drugs such as cocaine and methamphetamine.) Skip if jail does not screen for substance		12	Which of the follow services are available that apply. 1 Outpatient subst.	ole to indiv	riduals in th	nis jail? Sele	ect all		
	use disorders.			² ☐ Therapeutic com	munity witl	-		-	
	¹☐ A high majority (at least 75%)	Was the number provided		licensed provider				4 a l la a a l 4 la	
	² ☐ At least half (50%-74%) ³ ☐ Less than half (30%-49%)	¹☐ Estimated?		³ ☐ Services for co-conditions by a li			se and men	tai neaith	
	4 ☐ Few (15%-30%)	² ☐ Based on screening		⁴ ☐ Self-help meetings (e.g., Alcoholics Anonymous, SMART					
	⁵ Very few (less than 15%)	records?		Recovery)		,	-1	: c . A.	
l	⁶ Not able to estimate a range.		.	⁵ ☐ Other treatment	or recovery	/ services (please spec	шу).	
10	Excluding alcohol and marijuana, be protocols during the last 12 months common substances used by peop Rank the top 3 by placing a 1, 2, and common substances, with 1 being Example:	s, what were the 3 most le prior to booking? d 3 next to the 3 most	13	In the past 12 mont (e.g., live video con for providing substate) 1 Yes	ferencing '	with medic	al profession	onals)	
	Prescription opioids			2 $□$ No $→$ Skip to q	uestion 14				
	2 Heroin 3 Fentanyl		13	Has the number of use disorder via tel				bstance	
	T Cintarry		ŀ			anged sinc	G 2013:		
	Cocame or crack cocame			¹ Yes, it has increa ² Yes, it has decre					
	Methamphetamines			³☐ No, it has stayed					
	⁶ Prescription stimulants			•					
	Prescription opioids								
	² Heroin								
	Fentanyl (including carfentanyl)								
	Cocaine or crack cocaine								
	5 Methamphetamines								
	Prescription stimulants (e.g., Ad amphetamines legal with a pres								
	7 Hallucinogens (including PCP)								
	8 Other drugs (specify):								

13c Which of the following technology/methods are being used	16b Who is Buprenorphine made available to? Select all that apply.
to support participation in substance use treatment or recovery support for people in this jail? Check all that apply.	¹ ☐ Anyone with OUD who requests it
¹☐ Computers	² ☐ Pregnant women
² ☐ Tablets	³ ☐ People who were already receiving buprenorphine when booked into the jail
³ □ Portable kiosks	⁴ ☐ Individuals being released (e.g., induction pre-release)
⁴ ☐ Kiosks	⁵ ☐ Other criteria (specify):
⁵ ☐ Cell phones ⁶ ☐ Internet	
7 Text	
⁸ ☐ Email	
⁹ Video calls	
10 ☐ Other applications or software programs (please describe below):	17a Is Methadone (e.g., Methadose) provided to treat individuals with opioid use disorder?
	¹□ Yes
	² □ No → Skip to question 18a
	³☐ Not sure if methadone is available → Skip to question 18a
	17b Who is Methadone made available to? Select all that apply.
Has medication assisted treatment (MAT)¹ been available to individuals in this jail to treat their opioid use disorder	¹ ☐ Anyone with OUD who requests it
(OUD) in the past 12 months?	² ☐ Pregnant women
¹ Yes → Skip to question 16a	³ ☐ People who were already receiving methadone when booked into the jail
² □ No	⁴ □ Individuals being released
15 Why has MAT not been available to treat OUD in the past	5 ☐ Other (specify):
12 months?	
¹☐ We do not see many individuals with OUD	
 ² □ Policies prevent us from offering MAT ³ □ We do not have adequate staffing or staffing licensed to 	
provide MAT	18a Is Naltrexone (e.g., Vivitrol, ReVia, Depade) provided to treat
	10d) is italificable (e.g., vividio), itevia, bepade/ provided to field
⁴ ☐ MAT is too expensive / budget does not allow	individuals with opioid use disorder?
⁴ ☐ MAT is too expensive / budget does not allow ⁵ ☐ Other reasons (specify):	individuals with opioid use disorder?
	individuals with opioid use disorder? ¹☐ Yes, it is provided as a long acting injectable (Vivitrol) form ²☐ Yes, it is provided in tablet/pill form ³☐ Yes, it is provided in both forms
	individuals with opioid use disorder? 1 Yes, it is provided as a long acting injectable (Vivitrol) form 2 Yes, it is provided in tablet/pill form 3 Yes, it is provided in both forms 4 Yes, it is provided but not sure in which form
5 ☐ Other reasons (specify):	individuals with opioid use disorder? ¹☐ Yes, it is provided as a long acting injectable (Vivitrol) form ²☐ Yes, it is provided in tablet/pill form ³☐ Yes, it is provided in both forms ⁴☐ Yes, it is provided but not sure in which form ⁵☐ No → Skip to question 19
	individuals with opioid use disorder? ¹☐ Yes, it is provided as a long acting injectable (Vivitrol) form ²☐ Yes, it is provided in tablet/pill form ³☐ Yes, it is provided in both forms ⁴☐ Yes, it is provided but not sure in which form ⁵☐ No → Skip to question 19 ⁶ ☐ Not sure if naltrexone is available → Skip to question 19
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat	individuals with opioid use disorder? ¹ ☐ Yes, it is provided as a long acting injectable (Vivitrol) form ² ☐ Yes, it is provided in tablet/pill form ³ ☐ Yes, it is provided in both forms ⁴ ☐ Yes, it is provided but not sure in which form ⁵ ☐ No → Skip to question 19 ⁶ ☐ Not sure if naltrexone is available → Skip to question 19 18b Who is Naltrexone made available to? Select all that apply.
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder?	individuals with opioid use disorder? ¹
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? 1 ☐ Yes, it is provided in sublingual form (tablets/film placed	individuals with opioid use disorder? ¹
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder?	individuals with opioid use disorder? ¹
	individuals with opioid use disorder? ¹
	individuals with opioid use disorder? 1
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? 1 ☐ Yes, it is provided in sublingual form (tablets/film placed under the tongue) 2 ☐ Yes, it is provided in long-acting injectable form (Sublocade) 3 ☐ Yes, it is provided in both forms 4 ☐ Yes, it is provided but not sure in which form 5 ☐ No → Skip to question 17a	individuals with opioid use disorder? 1
	individuals with opioid use disorder? 1
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? 1 ☐ Yes, it is provided in sublingual form (tablets/film placed under the tongue) 2 ☐ Yes, it is provided in long-acting injectable form (Sublocade) 3 ☐ Yes, it is provided in both forms 4 ☐ Yes, it is provided but not sure in which form 5 ☐ No → Skip to question 17a	individuals with opioid use disorder? 1
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? 1 ☐ Yes, it is provided in sublingual form (tablets/film placed under the tongue) 2 ☐ Yes, it is provided in long-acting injectable form (Sublocade) 3 ☐ Yes, it is provided in both forms 4 ☐ Yes, it is provided but not sure in which form 5 ☐ No → Skip to question 17a	individuals with opioid use disorder? 1
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? 1 ☐ Yes, it is provided in sublingual form (tablets/film placed under the tongue) 2 ☐ Yes, it is provided in long-acting injectable form (Sublocade) 3 ☐ Yes, it is provided in both forms 4 ☐ Yes, it is provided but not sure in which form 5 ☐ No → Skip to question 17a	individuals with opioid use disorder? 1
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? 1 ☐ Yes, it is provided in sublingual form (tablets/film placed under the tongue) 2 ☐ Yes, it is provided in long-acting injectable form (Sublocade) 3 ☐ Yes, it is provided in both forms 4 ☐ Yes, it is provided but not sure in which form 5 ☐ No → Skip to question 17a	individuals with opioid use disorder? 1
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? 1 ☐ Yes, it is provided in sublingual form (tablets/film placed under the tongue) 2 ☐ Yes, it is provided in long-acting injectable form (Sublocade) 3 ☐ Yes, it is provided in both forms 4 ☐ Yes, it is provided but not sure in which form 5 ☐ No → Skip to question 17a	individuals with opioid use disorder? ¹
 Other reasons (specify): → Skip to question 19 Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? Yes, it is provided in sublingual form (tablets/film placed under the tongue) Yes, it is provided in long-acting injectable form (Sublocade) Yes, it is provided in both forms Yes, it is provided but not sure in which form No → Skip to question 17a Not sure if buprenorphine is available → Skip to question 17a Medication Assisted Treatment (MAT) is the use of medications, often 	individuals with opioid use disorder? 1
5 ☐ Other reasons (specify): → Skip to question 19 16a Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? 1 ☐ Yes, it is provided in sublingual form (tablets/film placed under the tongue) 2 ☐ Yes, it is provided in long-acting injectable form (Sublocade) 3 ☐ Yes, it is provided in both forms 4 ☐ Yes, it is provided but not sure in which form 5 ☐ No → Skip to question 17a 6 ☐ Not sure if buprenorphine is available → Skip to question 17a 1 Medication Assisted Treatment (MAT) is the use of medications, often in combination with behavioral therapies, to provide a whole-patient	individuals with opioid use disorder? ¹
 Other reasons (specify): → Skip to question 19 Is Buprenorphine (e.g., Suboxone, Subutex) provided to treat individuals with opioid use disorder? Yes, it is provided in sublingual form (tablets/film placed under the tongue) Yes, it is provided in long-acting injectable form (Sublocade) Yes, it is provided in both forms Yes, it is provided but not sure in which form No → Skip to question 17a Not sure if buprenorphine is available → Skip to question 17a Medication Assisted Treatment (MAT) is the use of medications, often 	individuals with opioid use disorder? 1

In the past 12 months, how many people with opioid u disorder received MAT while they were in custody?	any of the following in preparing for their release? Select all
1 A high majority (at least 75%) 2 At least half (50%-75%) 3 Less than half (30%-49%) 4 Few (15%-30%) 5 Very few (less than 15%) 6 Not able to estimate a range. 1 In the past 12 months, has Naloxone² (e.g., Narcan) be available for staff to reverse opioid overdoses³ within jail? 1 Yes 2 No	1 ☐ Schedule appointments with MAT providers in the community 2 ☐ Provide names of MAT providers in the community 3 ☐ Assist with completing intake paperwork for a community MAT provider 4 ☐ Facilitating exchange of information (e.g., medical records, treatment history) for a community MAT provider
	coach Arrange transportation to a MAT provider in the community
Email address: Phone number: Work address: Street: City: State:	
Zip code:	

FAQs

What is JCOIN and the National Survey of Substance Use Services in Jails?

The Justice Community Opioid Innovation Network, or JCOIN, is a National Institute on Drug Abuse (NIDA) research initiative to study approaches to increase high-quality care for people with opioid misuse and OUD in justice settings. The National Survey of Substance Use Services in Jails is a 15-minute survey that will help the field better understand the availability, accessibility, and use of substance use disorder services for persons involved in the criminal justice system. NORC at the University of Chicago, a non-profit research institution, is conducting this survey on behalf of JCOIN.

How will my data be used?

Upon receiving your survey in the mail, NORC will input your responses into our database and store your paper survey in a secure file cabinet. NORC will store your survey responses on a secure computer network server, and these data will only be accessible by members of the research team. Your responses will not be linked to any identifying information about you or your jail. They will be reviewed and analyzed together with all the responses from other participants and thus the research team will not be able to match your responses directly to you. We will not attribute any of your responses to you or your jail by name in future reports, publications or presentations resulting from this project.

What are the risks and benefits if I choose to participate?

Your decision to participate in this survey is voluntary. You can choose to skip any questions and you can stop participating at any time. There are no consequences for you if you want to stop. There are no known risks to participating in this survey other than a loss of time. While there are no direct benefits resulting from your participation, your responses will provide valuable new insights about the current screening and treatment practices for substance use disorders within jail settings and can help inform future policy decisions regarding substance use disorder treatment within correctional environments.

The Justice Community Opioid Innovation Network (JCOIN) offers free educational and technical assistance resources for staff working in justice agencies and related systems.

JCOIN Technical Assistance Resources:

With funding from the National Institute on Drug Abuse and the Bureau of Justice Assistance, JCOIN provides free technical assistance to justice systems to improve access to substance use disorder treatment for justice-involved individuals, and to facilitate practitioner and researcher partnerships. JCOIN's unique expertise is in measurement, evaluation, and research to support justice systems in improving substance use services. To learn more, visit the JCOIN website at https://www.jcoinctc.org/tta/.

JCOIN Web-Based Training Courses:

The JCOIN Training and Engagement Center (JTEC) is an online learning system that offers free courses for justice and treatment professionals. These courses draw on cutting-edge research by leading scientists in the field of addiction research. Offerings include in-depth courses on topics including overdose prevention, the efficacy of medications for opioid use disorder, addressing stigma around substance use, and other topics. Learners can register and earn course certificates for completion.

Additional JTEC resources include short courses on topics such as making graphs, charts, and biosketches. JTEC also offers a podcast in which research findings on opioids and related topics are distilled into brief, plain language discussions. Finally, a number of recorded webinars highlight JCOIN research findings.

JTEC is supported with funds from the National Institute on Drug Abuse and the Bureau of Justice Assistance. Browse the JTEC catalog or register for free online courses at https://www.jcoinctc.org/jtec/.